Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
November is Lung Cancer Awareness Month. What are you grateful for?
Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.
[powerpress]
Get more information about the ALEX Trial.
[ratingwidget post_id=0]
